Human adnasa I variant, a nucleic acid for coding, is used in the treatment of lung diseases or diseases to prepare practical drugs, as well as the pharmaceutical components containing the variant.

摘要

The present Invention relates to a variant of the amino acid sequence of Human DNase I that has a reduced binding Affinity for actin.The Invention provides Nucleic Acid sequences encoding these variantesr exsistentes to actin.Thus allowing the production of these variants in quantities sufficient for clinical use.The Invention also relates to pharmaceutical compositions and Uses of variantesresistentes to Actin ladnasa i human to prepare medicines.